Current Trends and Future Directions in Pancreatic Cancer Management: Review
DOI:
https://doi.org/10.12775/JEHS.2025.79.58420Keywords
PDAC, chemotherapy, immunotherapy, KRAS mutations, early diagnosisAbstract
Introduction:
Pancreatic cancer remains one of the most aggressive and lethal malignancies, characterized by late diagnosis, limited treatment options, and a poor overall prognosis. Advances in understanding the molecular and cellular mechanisms underlying this disease have opened pathways for innovative therapeutic approaches.
Purpose:
This review aims to summarize the current knowledge of pancreatic cancer, focusing on its pathophysiology, diagnostic challenges, and emerging therapeutic strategies, including targeted therapies, immunotherapy, and novel drug delivery systems.
Material and methods:
The literature review was performed by searching the PubMed and Google Scholar databases using the keywords "pancreatic cancer," "immunotherapy," "chemotherapy," and "diagnosis." Only articles published from 2012 onward were included in the analysis.
Results:
The review highlights significant progress in identifying genetic mutations, such as KRAS, TP53, and SMAD4, which drive pancreatic tumorigenesis. Diagnostic advancements, including liquid biopsies and molecular imaging, offer potential for earlier detection. Therapeutic innovations discussed include precision medicine approaches, such as inhibitors targeting KRAS mutations, immune checkpoint blockade therapies, and nanoparticle-based drug delivery systems. Early clinical trials show promise in improving response rates and survival outcomes, but challenges in resistance mechanisms and delivery efficiency persist.
Conclusion:
While pancreatic cancer remains a formidable challenge, recent advancements provide hope for improved management and outcomes. Continued multidisciplinary research and clinical trials are essential to translate these findings into effective standard-of-care treatments. This review underscores the importance of integrating novel therapies with conventional approaches to optimize patient outcomes.
References
1. Qadir RMAB, Umair MB, Tariq UB, Ahmad A, Kiran W, Shahid MH. Unraveling Pancreatic Cancer: Epidemiology, risk factors, and global trends. Cureus. 2024;16(11). doi: 10.7759/cureus.72816
2. Petersen GM, Boffetta P. Carcinogenesis of pancreatic cancer: Challenges, collaborations, progress. Molecular Carcinogenesis. 2011;51(1):1–2. https://doi.org/10.1002/mc.20876
3. Hu JX, Zhao CF, Chen WB, Liu QC, Li QW, Lin YY, et al. Pancreatic cancer: A review of epidemiology, trend, and risk factors. World Journal of Gastroenterology. 2021;27(27):4298–321. https://doi.org/10.3748/wjg.v27.i27.4298
4. Luo W, Wang J, Chen H, Ye L, Qiu J, Liu Y, et al. Epidemiology of pancreatic cancer: New version, new vision. Chinese Journal of Cancer Research. 2023;35(5):438–50. https://doi.org/10.21147/j.issn.1000-9604.2023.05.03
5. Kichi ZA, Rezaei Z, Soltani M, Farsani ZS. Molecular epidemiology and biology of pancreatic cancer among Iranian patients: an updated preliminary review. Advances in Translational Medicine. 2022;1–16. https://doi.org/10.55976/atm.120221391-16
6. Rawla P, Sunkara T, Gaduputi V. Epidemiology of Pancreatic Cancer: global trends, etiology and risk factors. World Journal of Oncology. 2019;10(1):10–27. https://doi.org/10.14740/wjon1166
7. Muratović B, Nikolić A. Epidemiology of pancreatic cancer. Zdravstvena Zastita. 2023;52(4):36–49. https://doi.org/10.5937/zdravzast52-47366
8. Ye T, Wang J, Zhao H, Zhao G, Li P. Role of N6 methyladenosine in the pathogenesis, diagnosis and treatment of pancreatic cancer (Review). International Journal of Oncology. 2022;62(1). https://doi.org/10.3892/ijo.2022.5452
9. Abidoye O, Cho YM, Bhushan S, Adewunmi C, Choudhury H. Trends in pancreatic cancer incidence and mortality in the United States from 2000 to 2019; a SEER based study. F1000Research. 2023;12:15. https://doi.org/10.12688/f1000research.122872.1
10. Molinari M, Liu H, Kaltenmeier C. Epidemiology and Risk Factors of Pancreatic Cancer. Pancreatic Cancer- Updates in Pathogenesis, Diagnosis and Therapies. IntechOpen; 2023. http://dx.doi.org/10.5772/intechopen.109778
11. Andersson G, Wennersten C, Borgquist S, Jirström K. Pancreatic cancer risk in relation to sex, lifestyle factors, and pre-diagnostic anthropometry in the Malmö Diet and Cancer Study. Biology of Sex Differences. 2016;7(1). https://doi.org/10.1186/s13293-016-0120-8
12. Desai K, Pereira K, Prabhakaran SY, Ali H, Thar YY, Choi E, et al. Anatomical and demographic prognosticators of pancreatic cancer. Journal of Clinical Oncology. 2024;42(16_suppl):e16310. https://doi.org/10.1200/jco.2024.42.16_suppl.e16310
13. Klein AP. Genetic susceptibility to pancreatic cancer. Molecular Carcinogenesis. 2011;51(1):14–24. https://doi.org/10.1002/mc.20855
14. Vimalachandran D, Ghaneh P, Costello E, Neoptolemos JP. Genetics and Prevention of pancreatic Cancer. Cancer Control. 2004;11(1):6–14. https://doi.org/10.1177/107327480401100102
15. Isaksson B, Jonsson F, Pedersen NL, Larsson J, Feychting M, Permert J. Lifestyle factors and pancreatic cancer risk: A cohort study from the Swedish Twin Registry. International Journal of Cancer. 2002;98(3):480–2. https://doi.org/10.1002/ijc.10256
16. Vimalachandran D, Ghaneh P, Costello E, Neoptolemos JP. Genetics and Prevention of pancreatic Cancer. Cancer Control. 2004;11(1):6–14. https://doi.org/10.1177/107327480401100102
17. Casari I, Falasca M. Diet and pancreatic cancer prevention. Cancers. 2015;7(4):2309–17. https://doi.org/10.3390/cancers7040892
18. Monroy-Iglesias MJ, Dolly S, Sarker D, Thillai K, Van Hemelrijck M, Santaolalla A. Pancreatic Cancer exposome profile to aid early detection and inform prevention strategies. Journal of Clinical Medicine. 2021;10(8):1665. https://doi.org/10.3390/jcm10081665
19. McAllister F, Leach SD. Targeting IL-17 for pancreatic cancer prevention. Oncotarget. 2014;5(20):9530–1. https://doi.org/10.18632/oncotarget.2618
20. Tez M, Sahingöz E, Martlı F. Molecular underpinnings of pancreatic cancer: Innovations in treatment and future perspectives. GIT. 2023;1. https://www.hksmp.com/journals/git/article/view/496
21. Pergolizzi RG, Brower ST. Molecular targets for the diagnosis and treatment of pancreatic cancer. International Journal of Molecular Sciences. 2024;25(19):10843. https://doi.org/10.3390/ijms251910843
22. Seufferlein T, Bachet JB, Van Cutsem E, Rougier P. Pancreatic adenocarcinoma: ESMO–ESDO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Annals of Oncology. 2012;23:vii33–40. https://doi.org/10.1093/annonc/mds224
23. Looi CK, Chung FFL, Leong CO, Wong SF, Rosli R, Mai CW. Therapeutic challenges and current immunomodulatory strategies in targeting the immunosuppressive pancreatic tumor microenvironment. Journal of Experimental & Clinical Cancer Research. 2019;38(1). https://doi.org/10.1186/s13046-019-1153-8
24. Cipora E, Czerw A, Partyka O, Pajewska M, Badowska-Kozakiewicz A, Fudalej M, et al. Quality of Life in Patients with Pancreatic Cancer—A Literature Review. International Journal of Environmental Research and Public Health. 2023;20(6):4895. https://doi.org/10.3390/ijerph20064895
25. Tonini V, Zanni M. Early diagnosis of pancreatic cancer: What strategies to avoid a foretold catastrophe. World Journal of Gastroenterology. 2022;28(31):4235–48. https://doi.org/10.3748/wjg.v28.i31.4235
26. Olczyk K. Pancreatic cancer - diagnosis, risk factors and treatment. Literature review. Journal of Education Health and Sport. 2023;17(1):178–92. https://doi.org/10.12775/jehs.2023.17.01.016
27. Hameed BS, Krishnan UM. Artificial Intelligence-Driven diagnosis of Pancreatic Cancer. Cancers. 2022;14(21):5382. https://doi.org/10.3390/cancers14215382
28. Poiraud M, Gkolfakis P, Arvanitakis M. Recent developments in the field of endoscopic ultrasound for diagnosis, staging, and treatment of pancreatic lesions. Cancers. 2023;15(9):2547. https://doi.org/10.3390/cancers15092547
29. Yamada R, Tsuboi J, Murashima Y, Tanaka T, Nose K, Nakagawa H. Advances in the early diagnosis of pancreatic ductal adenocarcinoma and premalignant pancreatic lesions. Biomedicines. 2023;11(6):1687. https://doi.org/10.3390/biomedicines11061687
30. Schuurmans M, Alves N, Vendittelli P, Huisman H, Hermans J. Setting the research agenda for clinical artificial intelligence in pancreatic adenocarcinoma imaging. Cancers. 2022;14(14):3498. https://doi.org/10.3390/cancers14143498
31. Sok CP, Polireddy K, Kooby DA. Molecular pathology and protein markers for pancreatic cancer: relevance in staging, in adjuvant therapy, in determination of minimal residual disease, and follow-up. HepatoBiliary Surgery and Nutrition. 2024;13(1):56–70. https://doi.org/10.21037/hbsn-22-628
32. Madadjim R, An T, Cui J. MicroRNAs in pancreatic cancer: Advances in biomarker discovery and therapeutic implications. International Journal of Molecular Sciences. 2024;25(7):3914. https://doi.org/10.3390/ijms25073914
33. Sirdeshmukh V, Gandhi M, Joshi H, Joshi PN, Kale A. Point of Care Electrochemical Aptasensor for Early Screening of Pancreatic Cancer. In: 2023 IEEE 16th International Conference on Nano/Molecular Medicine & Engineering (NANOMED). 2023 p. 83–6. doi: 10.1109/NANOMED59780.2023.10405174
34. Matsuno S, Satake K, Sunamura M, Go VLW. Advancements in pancreatic cancer research in Japan and unfolding prospective. Pancreas. 2004;28(3):217–8. https://doi.org/10.1097/00006676-200404000-00001
35. Spadi R. Current therapeutic strategies for advanced pancreatic cancer: A review for clinicians. World Journal of Clinical Oncology. 2016;7(1):27. https://doi.org/10.5306/wjco.v7.i1.27
36. Yip D, Karapetis C, Strickland A, Steer CB, Goldstein D. Chemotherapy and radiotherapy for inoperable advanced pancreatic cancer. Cochrane Database of Systematic Reviews. 2006;(3). https://doi.org/10.1002/14651858.cd002093.pub2
37. Xu YP. Advancement in treatment and diagnosis of pancreatic cancer with radiopharmaceuticals. World Journal of Gastrointestinal Oncology. 2016;8(2):165. https://doi.org/10.4251/wjgo.v8.i2.165
38. Li Z. Research of immunotherapy in pancreatic cancer. BIO Web of Conferences. 2024;111:02026. https://doi.org/10.1051/bioconf/202411102026
39. Sun H, Ma H, Hong G, Sun H, Wang J. Survival improvement in patients with pancreatic cancer by decade: A period analysis of the SEER database, 1981–2010. Scientific Reports. 2014;4(1). https://doi.org/10.1038/srep06747
40. Epidemiology, detection, and management of pancreatic cancer. Cancer Biology & Treatment. 2022;8(1):1–9. https://doi.org/10.24966/cbt-7546/100018
41. Yue W, Yang CS, DiPaola RS, Tan XL. Repurposing of metformin and aspirin by targeting AMPK-MTOR and inflammation for pancreatic cancer prevention and treatment. Cancer Prevention Research. 2014;7(4):388–97. https://doi.org/10.1158/1940-6207.capr-13-0337
42. Zagorodna O, Wang H, Wu X. Abstract B55: Chemoprevention of pancreatic cancer by targeting Kras mutations for apoptosis. Cancer Prevention Research. 2015;8(10_Supplement):B55. https://doi.org/10.1158/1940-6215.prev-14-b55
43. Zagorodna O, Wang H, Wu X. Abstract B82: Chemoprevention of pancreatic cancer by targeting Kras mutations for apoptosis. Cancer Research. 2015;75(13_Supplement):B82. https://doi.org/10.1158/1538-7445.panca2014-b82
44. Hocevar BA, Kamendulis LM, Pu X, Perkins SM, Wang ZY, Johnston EL, et al. Contribution of environment and genetics to pancreatic cancer susceptibility. PLoS ONE. 2014;9(3):e90052. https://doi.org/10.1371/journal.pone.0090052
45. Permuth J, Dezsi K, Vyas S, Ali K, Basinski T, Utuama O, et al. The Florida Pancreas Collaborative Next-Generation Biobank: Infrastructure to Reduce Disparities and Improve Survival for a Diverse Cohort of Patients with Pancreatic Cancer. Cancers. 2021;13(4):809. https://doi.org/10.3390/cancers13040809
46. Randriamahefa A, Fernandez-Zapico ME, Mladek AC, Evans L, Melbourne L, Osborne S, et al. The first initiative targeted to increase the training of African-American scientists in pancreatic cancer research. Pancreas. 2005;30(3):288–91. https://doi.org/10.1097/01.mpa.0000157480.22155.64
47. Telisnor G, Lim AS, Zhang Z, Lou X, Nassour I, Rogers SC. Abstract A076: Pancreatic cancer survival disparities in Florida using a statewide database. Cancer Epidemiology Biomarkers & Prevention. 2023;32(1_Supplement):A076. https://doi.org/10.1158/1538-7755.disp22-a076
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2025 Wojciech Firlej, Michał Nowak , Barbara Ufnalska , Anna Konarska , Anna Machowiak , Artur Fabijański , Mateusz Janik , Justyna Lisiecka , Joanna Rychlewska-Duda , Adriana Dukacz
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
The periodical offers access to content in the Open Access system under the Creative Commons Attribution-NonCommercial-ShareAlike 4.0
Stats
Number of views and downloads: 234
Number of citations: 0
